USPTO serial 78249512
FUSIONQUANT
Reviewed by CopyMark Law Group
Reg. 2930568Status 710
- Filing date
- Status date
- Registration date
- Mar 8, 2005
- Examiner
- GRAY, CAROLYN
- Law office
- TMO LAW OFFICE 111
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with FUSIONQUANT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Marseille, FR
Marseille, FR
Marseille, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Barry L. Kelmachter
BARRY L KELMACHTER BACHMAN & LAPOINTE, PCSTE 1201900 CHAPEL STNEW HAVEN, CT 06510Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma; pharmaceutical preparations for treatment of muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 9, 2015 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Mar 21, 2011 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 18, 2011 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 3, 2011 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 8, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 14, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 24, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 8, 2004 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 6, 2004 | ALIE | ASSIGNED TO LIE | — |
| Sep 30, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 15, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Aug 26, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2004 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Aug 26, 2004 | PAPER RECEIVED | — | |
| Jun 23, 2004 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 28, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2004 | PAPER RECEIVED | — | |
| Dec 11, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 13, 2003 | CFIT | CASE FILE IN TICRS | — |
| Aug 13, 2003 | CFIT | CASE FILE IN TICRS | — |
| Jul 23, 2003 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 23, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 23, 2003 | PAPER RECEIVED | — |